Administration of ON 01210.Na after exposure to ionizing radiation protects bone marrow cells by attenuating DNA damage response by Shubhankar Suman et al.
RESEARCH Open Access
Administration of ON 01210.Na after exposure to
ionizing radiation protects bone marrow cells by
attenuating DNA damage response
Shubhankar Suman1, Manoj Maniar2, Albert J Fornace Jr1 and Kamal Datta1*
Abstract
Background: Ionizing radiation-induced hematopoietic injury could occur either due to accidental exposure or
due to diagnostic and therapeutic interventions. Currently there is no approved drug to mitigate radiation toxicity
in hematopoietic cells. This study investigates the potential of ON 01210.Na, a chlorobenzylsulfone derivative, in
ameliorating radiation-induced hematopoietic toxicity when administered after exposure to radiation. We also
investigate the molecular mechanisms underlying this activity.
Methods: Male C3H/HeN mice (n = 5 mice per group; 6-8 weeks old) were exposed to a sub-lethal dose (5 Gy) of g
radiation using a 137Cs source at a dose rate of 0.77 Gy/min. Two doses of ON 01210.Na (500 mg/kg body weight)
were administered subcutaneously at 24 h and 36 h after radiation exposure. Mitigation of hematopoietic toxicity by
ON 01210.Na was investigated by peripheral white blood cell (WBC) and platelet counts at 3, 7, 21, and 28 d after
radiation exposure. Granulocyte macrophage colony forming unit (GM-CFU) assay was done using isolated bone
marrow cells, and terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) was performed on bone
marrow sections at 7 d post-exposure. The DNA damage response pathway involving ataxia telangiectasia mutated
(ATM) and p53 was investigated by Western blot in bone marrow cells at 7 d post-exposure.
Results: Compared to the vehicle, ON 01210.Na treated mice showed accelerated recovery of peripheral WBC and
platelet counts. Post-irradiation treatment of mice with ON 01210.Na also resulted in higher GM-CFU counts. The
mitigation effects were accompanied by attenuation of ATM-p53-dependent DNA damage response in the bone
marrow cells of ON 01210.Na treated mice. Both phospho-ATM and phospho-p53 were significantly lower in the
bone marrow cells of ON 01210.Na treated than in vehicle treated mice. Furthermore, the Bcl2:Bax ratio was higher
in the drug treated mice than the vehicle treated groups.
Conclusions: ON 01210.Na treatment significantly mitigated the hematopoietic toxicity induced by a sub-lethal
radiation dose. Mechanistically, attenuation of ATM-p53 mediated DNA damage response by ON 01210.Na is
contributing to the mitigation of radiation-induced hematopoietic toxicity.
Keywords: Radiation toxicity, hematopoietic toxicity, ON 01210.Na, Ex-RAD, radiation mitigation, DNA damage.
Background
In addition to therapeutic and diagnostic interventions,
exposure to sub-lethal doses of radiation to civilian popu-
lation may occur during radiological accidents or terror
attacks [1,2]. Depending on the duration of exposure, the
area exposed, and the dose received, radiation exposure
in the immediate aftermath could lead to a myriad of
deleterious effects, including acute radiation syndrome
(ARS) [3]. ARS is a well-defined dose-dependent pattern
of organ damage, mainly affecting tissues with rapidly
proliferating cells [4,5]. ARS includes hematopoietic syn-
drome (1 Gy to 8 Gy), gastrointestinal syndrome (> 8 Gy)
and cardiovascular/CNS syndrome (> 20 Gy) and follows
well defined pathologies [5,6]. Acute radiation exposure
in the range between 1 and 8 Gy leads to a drop in
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circulating blood cells [7]. At the higher end of this radia-
tion dose range, blood cell counts continue to decline
due to the demise of bone marrow stem/progenitor cells
leading to lethality. Blood cell counts also decline at
lower doses, until surviving precursor cells proliferate to
restore homeostasis [5]. During this period of declining
bone marrow cells, individuals are at an increased risk of
infection and hemorrhage [8]. A number of plant/herbal
products, like Hippophae rhamnoides and Mentha arven-
sis and chemical entities, like amifostin and vitamin E
related products, have been shown to modulate radiation
toxicity. However, very few have been shown to have
radiomitigator properties and fewer have been shown to
improve hematological parameters [9,10]. Therefore,
therapeutic agents mitigating radiation-induced decrease
in bone marrow cells could play an important role not
only in emergency situations but also in minimizing the
radiation toxicity to bone marrow during radiation ther-
apy or diagnostic procedures.
The tumor suppressor p53 plays a vital role in radia-
tion-induced DNA damage response (DDR) and cell
death [11]. The DDR starts with the sensing of the
DNA damage, which is then conveyed to effectors via
signal transducers. The ataxia telangiectasia mutated
(ATM) protein is a well-established sensor of DNA
damage and gets activated by autophosphorylation on
sensing DNA damage [12]. Activated ATM in turn
phosphorylates its downstream target p53, which is con-
sidered a signal transducer of DDR, to effectors like
Bcl2-associated X protein (Bax), p21, and B-cell lym-
phoma 2 (Bcl2), to either induce cell cycle arrest for
repair or initiate programmed cell death if the damage
is beyond repair. It is important to note here that phos-
phorylation of p53 leads not only to its activation but
also to its stabilization by minimizing its interaction
with murine double minute 2 (MDM2), a negative regu-
lator of p53 [13]. DNA damage-induced activation of
p53 is known to regulate the transcription of two major
cell death regulators: anti-apoptotic Bcl2 and pro-apop-
totic Bax via down-regulation and trans-activation,
respectively [11,14-16]. Bcl2 inhibits apoptosis by antag-
onizing Bax oligomerization, which is indispensible for
Bax-mediated apoptosis [17]. In previous in vitro studies
ON 01210.Na has been reported to reduce the level of
p53 and its target p21 and Bax, when given prophylacti-
cally before radiation exposure [18]. Here we report that
administration of 2 doses of ON 01210.Na at 24 and 36
h after radiation exposure augmented hematopoietic cell
survival through reduction in DNA damage and damage
response. Our results also indicate that increased clono-
genic survival of bone marrow cells observed in ON




Six to eight week old C3H/HeN male mice were pur-
chased from Charles River Laboratories (Wilmington,
MA, USA) and were housed in the Georgetown Univer-
sity’s (GU) AAALACI (Association for Assessment and
Accreditation of Laboratory and Animal Care Interna-
tional) accredited facility. All the animal procedures were
performed according to protocols approved by the Geor-
getown University Animal Care and Use Committee
(GUACUC), and terminal anesthesia with CO2 was used
for collection of tissue and blood samples from these
mice. For irradiation, mice were placed in a circular pie
shaped, well-ventilated plastic mouse holder, and a 137Cs
source (dose rate 0.77 Gy/min) was used as g radiation
source. Effects in irradiated+ON 01210.Na treated groups
were compared to those in the radiation only and the
radiation+vehicle treated groups and are shown in the
results. The unirradiated control, drug only group, and
vehicle only group acted as additional control groups. All
irradiation groups were exposed to 5 Gy of g radiation,
control groups were sham irradiated and irradiation and
experiments were repeated two times.
ON 01210.Na formulation and administration
ON 01210.Na (Ex-RAD), a chlorobenzylsulfone deriva-
tive developed by Onconova Theraputics (Newtown, PA,
USA) as a radioprotector and mitigator, was described
earlier [18-20]. ON 01210.Na (500 mg/kg) was adminis-
tered subcutaneously (SC), using 1 mL sterile syringe
with a 25G needle at 24 and 36 h after 5 Gy radiation
exposure.
Peripheral white blood cell (WBC) and platelet counts
Blood samples (n = 5 mice per group per time point)
were collected by cardiac puncture in ethylenediamine-
tetra acetic acid (EDTA) tubes after terminal CO2
anesthesia at 3, 7, 21, and 28 d after radiation exposure
and subjected to complete blood count. White blood
cell (WBC) counts, neutrophil counts, and monocyte
counts are presented as absolute count, and platelet
counts are presented as percent of normal count (1.2 ×
106 per μL of blood, ± 16.1 standard error of mean).
Bone marrow histopathology
Bone marrow (n = 5 mice per group) was used for his-
topathologic analysis. Femurs were surgically removed
from each mouse at 7 d after 5 Gy radiation exposure,
fixed in 10% buffered formalin for 48 h, decalcified, par-
affin embedded, and 5 μm thick sections were stained
with hematoxylin and eosin (H&E) using standard pro-
cedures. Unstained sections were used for terminal
deoxynucleotidyl transferase dUTP nick end-labeling
Suman et al. Radiation Oncology 2012, 7:6
http://www.ro-journal.com/content/7/1/6
Page 2 of 9
(TUNEL) assay. Bone marrow cellularity in H&E stained
sections was semiquantitatively scored (in 5 mice from
each group) by counting nucleated cells in a 16-square
(1 cm2 each) grid in randomly chosen 5 high-power
(40×) microscopic fields for each section (3 sections
from each mouse) as described earlier [21]. While plot-
ting the results, control section cellularity was consid-
ered 100 percent. Megakaryocytes were also evaluated
by a semi-quantitative analysis of three adjacent high-
power (40×) microscopic fields (n = 5 and 3 sections
from each mouse were scored).
Granulocyte Macrophage-Colony Forming Unit (GM-CFU)
assay
Mice (n = 5 mice per group) were euthanized at 7 d after
radiation exposure. Under aseptic conditions femurs were
excised, ends opened, and bone marrow cells collected by
flushing. For flushing, Iscove’s modified Dulbecco’s med-
ium (IMDM) (StemCell Technologies, Vancouver, BC,
Canada) supplemented with 5% fetal bovine serum (FBS)
was used with sterile syringes and 25G needles. Flushed
bone marrow from each femur was pipetted up and down
to prepare a single cell suspension and passed through 70
micron nylon meshes (BD Biosciences, Sparks, MD, USA).
Isolated cells were counted using a cell counter (Beckman
Coulter, Brea, CA, USA), and from each femur 2.5 × 104
cells/mL were plated in triplicate in ultra-low attachment
60 mm dishes (Corning, NY, USA) using methocult
(M3534, StemCell Technologies) medium supplemented
with 10 ng/mL granulocyte macrophage colony stimulat-
ing factor (GM-CSF) (StemCell Technologies). The plates
were incubated at 37°C in 5% CO2 and ≥ 95% humidity
for 7 d, and colonies were counted using a dissecting
microscope (Leica, Wetzlar, Germany).
Apoptosis detection in bone marrow and spleen
DNA damage and cell death in bone marrow and spleen
cells (n = 5 mice per group) were detected, using the
ApopTag Plus Peroxidase in situ apoptosis detection kit
(S7101, Millipore, Billerica, MA, USA) according to manu-
facturer’s instruction. Briefly, tissue sections were deparaf-
finized and pretreated with Proteinase-K solution (20 μg/
mL) at room temperature for 15 min. The endogenous
peroxidase activity was quenched using 3% hydrogen per-
oxide in phosphate buffered saline (PBS) at room tempera-
ture. Following incubation with terminal deoxynucleotidal
transferase (TdT) at 37°C for 1 h, the apoptotic cells were
visualized under a bright field microscope by a diamino-
benzidine (DAB) based detection system supplied with the
kit, and sections were counterstained using methyl green
(Trevigen, Gaithersburg, MD, USA) nuclear stain. TUNEL
positive cells were counted in 5 randomly chosen high
power fields (40×), and counts from 3 sections from each
mouse were used for statistical analysis.
Western blot
Bone marrow cells were isolated, as per the protocol
described in the previous section, and cells from 5 mice
were pooled for the Western blot analysis. Cells were
lysed in ice-cold protein extraction buffer (0.5% Sodium
deoxycholate, 0.5% NP-40, 10 mM EDTA in PBS) con-
taining protease inhibitor cocktail (Sigma, St. Louis,
MO, USA). The homogenate was centrifuged at 12000
xg at 4°C for 10 min and supernatant was collected. The
Bradford protein assay was used to quantify the protein
concentration in respective samples. Equal amounts of
protein samples were mixed with the appropriate
volume of Laemmli’s sample buffer (6× solution: 375
mM Tris-HCl (pH = 6.8), 6% sodium dodecyl sulphate
(SDS), 48% Glycerol, 9% b-Mercapto-ethanol and 0.03%
bromophenol blue), heated at 95°C for 5 min, and were
resolved on SDS- polyacrylamide gel electrophoresis
(PAGE). Proteins were transferred onto a polyvinylidine
fluoride (PVDF) membrane, blocked with 5% milk in
tris-buffered saline with 0.1% Tween (TBST), and incu-
bated with appropriate primary antibody (p-ATM
(1:100, Sc-47739, Clone-10H11-E12); p53 (1:500, Sc-98,
Clone-1801); p-p53 (1:200, Sc-18078, Clone-mSer20);
Bcl-2 (1:250, Sc-7382, Clone-C-2); Bax (1:250, Sc-7480,
Clone-B-9) and b-actin (1:2000, Sc-47778, Clone-C4)
from Santa Cruz Biotechnology, Santa Cruz, CA, USA.
Western blot membranes were developed with horserad-
ish peroxidase (HRP) conjugated secondary antibody
and enhanced chemiluminescence (ECL) detection sys-
tem (Cat# 34080, Thermo Fisher Scientific, Rockford,
IL, USA). Images were captured on photographic films
and scanned. Results from a representative experiment
are displayed. Scanned images of the Western blots
were quantified by ImageJ v4.44 software using the pre-
viously described protocol [22]. Briefly, scanned images
were opened in ImageJ, and bands were selected using
the rectangular selection tool to generate band profile
plots. Normalized band intensity was generated using b-
actin band intensity in respective columns.
Statistical analysis
Statistical analysis to find significance between two
groups was performed using two tailed paired Stu-
dent’s t-test, and p < 0.05 was taken as statistically sig-
nificant. Error bars represent ± standard error of mean
(SEM).
Results
Accelerated recovery of peripheral blood cell count and
increased clonogenic survival of bone marrow
progenitors in ON 01210.Na treated group
The WBC count at 3 d showed uniform reduction in all
the irradiated groups. However, at 7 and 21 d signifi-
cantly higher counts were observed in mice treated with
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ON 01210.Na (compared to respective radiation+vehicle
groups p < 0.04 for 7 d and p < 0.01 for 21 d) (Figure
1A). A significant difference in absolute neutrophil
count (ANC) was also observed between the ON 01210.
Na treated and the vehicle treated groups at 7 and 21 d
(p < 0.05 for both of the time points) (Figure 1B). When
absolute monocyte counts (AMC) were compared
between the ON 01210.Na and the vehicle treated
groups, a significant difference was observed at 21 d (p
< 0.05) (Figure 1C). In contrast to WBC count, platelet
count was decreased at 7 d and recovery was observed
at 21 d. However, at 7 d the count was significantly
higher in the ON 01210.Na treated group than the vehi-
cle treated group (p < 0.05), and at 21 d the ON 01210.
Na treated group showed greater recovery than the vehi-
cle group (p < 0.05) (Figure 1D). Furthermore, total cel-
lularity, as well as megakaryocyte counts in bone
marrow sections, was significantly higher in the ON
01210.Na than in the vehicle treated mice (Figure 2A, B,
and 2C). When given 24 h and 36 h after radiation
exposure, the ON 01210.Na treated group also showed
significantly enhanced clonogenic survival of bone mar-
row cells (p < 0.0005 compared to the radiation+vehicle
group) (Figure 3).
ON 01210.Na treatment showed reduction in apoptotic
cells in bone marrow and spleen
TUNEL assay on bone marrow and spleen sections from
the ON 01210.Na treated groups showed fewer apopto-
tic cells than the vehicle treated group (Figure 4A and
4C). Quantification of TUNEL positive cells indicating
apoptosis showed significantly lower counts in the ON
01210.Na treated group than the vehicle treated group
in both the bone marrow and spleen samples (Figure 4B
and 4D; p < 0.01 for bone marrow and p < 0.05 for
spleen compared to radiation+vehicle groups).
Figure 1 Post-exposure peripheral blood cell count with or without ON 01210.Na treatment. A) Absolute peripheral WBC counts. B)
Absolute neutrophil count (ANC). C) Absolute monocyte counts (AMC). D) Platelet count expressed as percent of normal count. R+V: 5 Gy
radiation+vehicle; R: 5 Gy radiation; R+D: 5 Gy radiation+drug (ON 01210.Na). *p < 0.05 compared to radiation+vehicle.
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Attenuated DNA damage response in bone marrow cells
of ON 01210.Na treated mice
The DNA damage response pathway involving ATM
and p53 was assessed by Western blot analysis. Com-
pared to vehicle treated groups, we observed a signifi-
cant reduction of total p53, phospho-ATM, and
phospho-p53 levels in ON 01210.Na treated bone mar-
row cells at 7 d post-radiation (Figure 5A and 5D).
Decrease of the p53 level in ON 01210.Na treated mice
was associated with increase in anti-apoptotic Bcl2 and
decrease in pro-apoptotic Bax (Figure 5A). Quantifica-
tion of Western blots showed significant decrease in
total p53 and Bax but increase in Bcl2 (Figure 5B; p <
0.002 for p53, < 0.001 for Bax, and < 0.007 for Bcl2
compared to radiation+vehicle groups). Interestingly, the
Bcl2:Bax ratio was markedly greater in the ON 01210.
Na treated than the vehicle treated mice (Figure 5C).
Furthermore, quantification of phospho-ATM and phos-
pho-p53 showed significant decrease in the ON 01210.
Na treated mice (Figure 5E; p < 0.0007 for p-ATM and
< 0.0002 for the p-p53 compared to the radiation+vehi-
cle treated mice).
Figure 2 Quantification of bone marrow cellularity in H&E stained sections at 7 d post-radiation. A) Photomicrograph showing H&E
stained sections of bone marrow at 40× magnification. B) Relative quantification of total bone marrow cellularity. *p < 0.004 compared to
radiation+vehicle (R+V). C) Megakaryocyte counts in H&E stained bone marrow sections. *p < 0.02 compared to radiation+vehicle. Control: no
radiation, ON 01210.Na or vehicle; R: 5 Gy radiation; R+V: 5 Gy radiation+vehicle; R+D: 5 Gy radiation+drug (ON 01210.Na).
Figure 3 Granulocyte-macrophage colony forming units (GM-
CFU) assay of bone marrow cells at 7 d post-radiation. *p < 0.005
compared to radiation+vehicle (R+V). Control: no radiation, ON 01210.
Na or vehicle; R: 5 Gy radiation; R+V: 5 Gy radiation+vehicle; R+D: 5 Gy
radiation+drug (ON 01210.Na).
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Discussion
Terrorist threats and recent accidents in nuclear instal-
lations emphasize the need to develop strategies to miti-
gate radiation toxicity [23]. Mitigation of radiation
toxicity also has implications for radiation therapy [3].
In this initial investigation we have shown that two
doses of ON 01210.Na, administered 24 h and 36 h
after radiation exposure, could significantly mitigate
radiation-induced hematopoietic toxicity. Mechanisti-
cally, ON 01210.Na treatment resulted in diminished
radiation-induced DDR and apoptosis. Overall, ON
01210.Na was able to accelerate the post-exposure
hematopoietic recovery process as evidenced by a
greater increase in peripheral WBC and platelet counts,
higher bone marrow cellularity, and higher number of
GM-CFUs in the drug treated groups than in the vehicle
groups.
Most of the post-radiation hematopoietic morbidity
and mortality is attributed to infection and hemorrhage
due to leukopenia and thrombocytopenia resulting from
Figure 4 TUNEL staining of bone marrow and spleen sections at 7 d post-radiation. A) Photomicrograph showing TUNEL staining of bone
marrow sections at 20× magnification. B) Quantification of TUNEL positive cells in bone marrow sections. *p < 0.01 compared to radiation
+vehicle (R+V). C) Photomicrograph showing TUNEL staining of spleen sections at 20× magnification. D) Quantification of TUNEL positive cells in
spleen sections. *p < 0.05 compared to radiation+vehicle. Control: no radiation, ON 01210.Na or vehicle; R: 5 Gy radiation; R+V: 5 Gy radiation
+vehicle; R+D: 5 Gy radiation+drug (ON 01210.Na).
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loss of bone marrow cells. Our time course study ranging
from 3 to 28 d demonstrated faster recovery of radiation-
induced WBC cell loss in the ON 01210.Na than in the
vehicle treated groups. Higher numbers of peripheral
WBC counts in the ON 01210.Na treated animals led us
to believe that the drug is aiding in quicker regeneration
and turnover of bone marrow cells than the vehicle
groups through proliferation of surviving precursor cells.
Importantly, at 7 d and at 21 d in the ON 01210.Na
groups, the absolute neutrophil counts were significantly
higher which would equip these animals to resist any
potential post-radiation infection better than the vehicle
treated groups. Furthermore, the ON 01210.Na treated
groups at both these time points showed greater percent
of platelets than the vehicle groups, which would mini-
mize not only post-radiation infection but would also
reduce the risk of hemorrhagic events.
Bone marrow progenitor cells with an average lower
radiosensitivity than the more primitive hematopoietic
precursor cells are a rapidly cycling cell population and
are capable of forming colonies in culture (reviewed by
[24]). Our results from the GM-CFU assay support the
notion that ON 01210.Na is enhancing the recovery and
regeneration of the progenitor cells, which survived
initial radiation-induced damage. Mechanistic investiga-
tion further supports our hypothesis that ON 01210.Na
is accelerating recovery/regeneration of bone marrow
cells due to attenuation of DDR. The ON 01210.Na,
through lowering of phospho-ATM and p53, along with
a higher Bcl2/Bax ratio, could be aiding in the prolifera-
tion of the surviving cells. Our results showing diminu-
tion of p53 level, along with increase in Bcl2 and
decrease in Bax level, demonstrate the mechanism of
ON 01210.Na mediated radiation mitigation and is
Figure 5 Western blot analysis of DNA damage response in bone marrow cells at 7 d post-radiation. A) Scanned images showing
Western blot of p53, Bcl2, and Bax. B) Densitometric quantification of p53, Bcl2, and Bax. *p < 0.002 for p53, < 0.001 for Bax, and < 0.007 for
Bcl2 compared to respective radiation+vehicle groups C) Bcl2/Bax ratio. *p < 0.005 compared to radiation+vehicle. D) Western blot images of
phospho-ATM and phospho-p53. E) Densitometric quantification of phospho-ATM and phospho-p53. *p < 0.0007 for p-ATM and < 0.0002 for p-
p53 compared to radiation+vehicle treated mice. R+V: 5 Gy radiation+vehicle; R: 5 Gy radiation; R+D: 5 Gy radiation+drug (ON 01210.Na).
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important for the management of radiation exposure to
healthy tissues.
Bone marrow and spleen are important in maintaining
peripheral blood cell pool and proper functioning of the
immune system. Thus, radiation damage to these vital
organs can affect hematopoiesis as well as immune defense,
which are critical determinant of post-exposure morbidity
and mortality [25,26]. Although chemical entities and her-
bal preparations have been investigated for their radiopro-
tection and radiomitigation properties, we are yet to have
an approved pharmacological agent to counter radiation
damage to critical tissues, like bone marrow, and to reduce
subsequent morbidity and mortality [27]. Compounds like
statins and palifermin has been shown to mitigate radiation
mucositis and enteropathy, and herbal preparations from
Hippophae rhamnoides and Mentha arvensis have shown
significant hematopoietic protection [3,9,10]. However,
there are presently no approved agents available to mitigate
radiation-induced hematopoietic toxicity. In a post-expo-
sure scenario, administration of ON 01210.Na was able to
reduce the number of apoptotic cells (TUNEL positive) in
both bone marrow and spleen, indicating lower cell death
than that with vehicle treatment. Our Western blot results
suggest that lessening of cell death in bone marrow and
spleen has to be p53 mediated and is dependent on the
activated ATM. Although we did not observe any altera-
tions in total ATM levels (data not shown), we did find sig-
nificantly lower levels of activated phospho-ATM and,
consequently, significantly reduced phospho-p53 in the
ON 01210.Na treated bone marrow cells. Stability of p53 is
dependent on its phosphorylation status [12]. We believe
that decreased total p53 in bone marrow cells is due to
reduced phosphorylation of p53, allowing enhanced inter-
action with MDM2, leading to increased ubiquitinylation
and subsequent degradation. Pro-apoptotic Bax and anti-
apoptotic Bcl2 are under the regulation of tumor suppres-
sor p53. Antagonizing Bax and enhancing Bcl2 has been
shown to confer resistance on cells to ionizing radiation
[28,29]. Reduction in activated ATM and p53 levels leading
to a decrease in DDR signal, is playing a role in enhanced
hematopoietic recovery in ON 01210.Na treated mice.
Conclusions
Taken together, we conclude that the post-exposure
administration of ON 01210.Na enhances the recovery
of hematopoietic cells by employing a mechanism that
not only attenuates DNA damage sensing and damage
signal transduction but also alters levels of effectors like
Bax and Bcl2.
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